The effect of an antifungal agent, amphotericin B, on human and canine neutrophil metabolism was studied. Commercial preparations of amphotericin B in concentrations ranging from 5 to 100 yg/ml stimulated neutrophil chemiluminescence in the presence of 10-M luminol. This response was blocked by 2-deoxyglucose, a metabolic inhibitor, and by the absence of extracellular calcium ions. Neither pure amphotericin B nor the solubilizing agent present in the commercial preparation, alone or in combination, stimulated neutrophil chemiluminescence. Commercial amphotericin B caused an increase in oxygen uptake by neutrophils but no detectable superoxide anion production. Neutrophils were injured by commercial amphotericin B, as shown by an increase in trypan blue dye uptake but not cell lysis. Binding of amphotericin B to neutrophil membrane sterol with a subsequent alteration in membrane configuration is the most likely cause of metabolic stimulation.
Amphotericin B, a polyene antibiotic, has been used in the treatment of systemic fungal disease since 1957. The major problem with its use has been toxicity (18) ; the intravenous form of amphotericin B frequently causes local thrombophlebitis, fever, chills, nausea, vomiting, headache, anorexia, hypokalemia, abnormal renal function, and anemia. These side effects limit the amount of drug that can be given intravenously.
The antifungal action of amphotericin B depends upon its binding to cell membrane sterol (14) which causes potassium leakage and death of the fungus (15) . These effects are blocked in the media by ergosterol, which binds to the amphotericin B and prevents it from adhering to the fungal cell membrane (16) . Amphotericin B also can bind to human erythrocyte membranes, causing potassium leakage, free influx of sodium, and osmotic cell lysis (8) . Free cholesterol can prevent erythrocyte lysis by competing with membrane cholesterol for amphotericin B binding (16) . DeKruijef and Demel (12) suggested that eight amphotericin B-cholesterol complexes can combine on one side of a membrane to form half of a pore through the membrane lipid bilayer. A complete pore can result if a similar complex develops on the opposite membrane surface. Since the phospholipid:cholesterol ratio in neutrophil membranes is similar to that in erythrocyte membranes (20) The effect of 2-deoxyglucose, a known metabolic inhibitor of neutrophils (11), on the chemiluminescent response to amphotericin B was studied. Neutrophils were washed and resuspended in glucose-free HBSS. 2-Deoxyglucose (10 mM) was added to the cell preparation, and commercial amphotericin B was added as a stimulus. Commercial amphotericin B added to neutrophils in glucose-free HBSS served as a control. 2-Deoxyglucose caused a marked inhibition of neutrophil chemiluminescence (Fig. 2) . When N-ethylmaleimide (0.1 mM), another metabolic inhibitor (11), was incubated with neutrophils, there was no chemiluminescent response to commercial amphotericin B as compared to a peak of 4 .0 x 104 cpm in the absence of N-ethylmaleimide.
The effects of divalent cations, calcium and magnesium, on chemiluminescence were studied. Neutrophils were resuspended in magnesium-free HBSS, calcium-free HBSS, or calcium-and magnesium-free HBSS. Neutrophils in complete HBSS (containing both 1 added, and the chemiluminescent response of neutrophils was observed. In the presence of calcium even without magnesium the chemiluminescent response was not significantly different from the control; but in the absence of calcium even in the presence of magnesium, there was no significant chemiluminescence (Fig. 3) .
Oxygen uptake studies. of the neutrophils were nonviable as determined by the inability to exclude the dye, compared with 2% of control neutrophils. DISCUSSION Studies by Bjorksten et al. (6) have shown that amphotericin B (5 to 20 ,Ig/ml) pretreatment of neutrophils suppressed the chemiluminescent response to opsonized zymosan. These authors, however, did not examine the capacity of amphotericin B itself to stimulate neutrophils to emit light. Our study has shown that commercial amphotericin B induced strong chemiluminescence in the presence of luminol, whereas pure amphotericin B plus luminol gave a much weaker response. The chemiluminescence of commercial amphotericin B was not due to sodium deoxycholate used as a solubilizing agent in the commercial preparation because there was no light emission from neutrophils in contact with sodium deoxycholate alone. When the mixture of pure amphotericin B and sodium deoxycholate with or without phosphate was used to stimulate neutrophils, the light emission was still much lower than from commercial amphotericin B. Commercial amphotericin B is a submicroscopic colloidal suspension (4), whereas pure amphotericin B and other mixtures used in our study were not colloids. In the colloidal form commercial amphotericin B appears to have a greater in vivo effect and increased toxicity to both animals and humans (5) . Our studies indicated that the colloidal state of amphotericin B as found in the commercial preparation was required for optimal stimulation of neutrophil chemiluminescence.
In 1977, Cohen and Chovaniec (11) showed that the metabolic response of neutrophils harvested from the peritoneal cavity of guinea pigs was blocked by 2-deoxyglucose and N-ethylmaleimide. This was determined by measuring the production of superoxide anion. In the present study the chemiluminescent response to commercial amphotericin B was markedly inhibited by 2-deoxyglucose and N-ethylmaleimide, which suggests that metabolic stimulation was responsible for the chemiluminescence induced by commercial amphotericin B. However, as compared with opsonized zymosan, commercial amphotericin B caused only a small amount of oxygen uptake in neutrophils, and no superoxide anion could be detected. This suggests that the chemiluminescence from amphotericin Btreated neutrophils is the result of a low-level metabolic response that results in some oxygen uptake but too little superoxide production to be detectable.
The mechanism by which amphotericin B caused stimulation of neutrophil metabolism and chemiluminescence probably involves the binding of amphotericin B to cholesterol on neutrophil membranes. DeKruijef and Demel (12) have shown that amphotericin B can bind to cholesterol to form complexes in the membranes of Acholeplasma laidawii cells, causing pores through half the thickness of the membrane. The hydrophilic channel of this pore has a diameter of about 0.8 nm. Van Zutphen et al. (19) and Cass et al. (9) found that this half-pore decreased the membrane electrical resistance to a significant extent, and Cass et al. (9) found that it is anion selective and discriminates among anions on the basis of their size. Previous data (8, 9, 12, 15, 19) have shown that amphotericin B can cause cell membrane injury. Our data demonstrated an increase in trypan blue dye uptake by neutrophils after incubation with amphotericin B, suggesting that it was causing an increase in membrane permeability to the dye. Chunn et al. (10) have shown that the neutrophil toxicity of amphotericin B as measured by trypan blue uptake could be blocked by cholesterol, suggesting that the free cholesterol was competing with membrane cholesterol binding sites of amphotericin B. This amphotericin B-cholesterol interaction may be the primary event leading to neutrophil metabolic stimulation. The activation of neutrophil metabolism secondary to binding with membrane cholesterol is analogous to the stimulatory effect of streptolysin 0 on neutrophils as reported by Andersen and Duncan (2) . Streptolysin 0, which has no known enzymatic activity, appears to be capable of stimulating metabolic activity by virtue of its cholesterol-binding ability. The requirement of extracellular calcium for the neutrophil metabolic response to the stimulus formylmethionylleucylphenylalanine has been shown by Simchowitz and Spilberg (17) . We also showed that extracellular calcium was necessary in the chemiluminescent response of neutrophil to commercial amphotericin B. Amphotericin B appears to have caused some membrane alteration which results in a calcium-dependent stimulation of neutrophil metabolism.
These studies indicate that amphotericin B in the colloidal state can cause metabolic activation of neutrophils and an associated chemiluminescence. The toxic properties of amphotericin B may be, in part, related to this phenomenon.
